{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:12:03Z","timestamp":1787015523350,"version":"build-2736575974"},"reference-count":86,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T00:00:00Z","timestamp":1501804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Medications should be employed with caution in women of childbearing age who are pregnant or considering pregnancy. Compared to oral or parenteral agents, topical medications have limited systemic absorption and are deemed safer. However, their safety profile must be assessed cautiously due to the limited available data. In this article, we aggregate human and animal studies to provide recommendations on utilizing topical antiviral and antifungal medications in pregnancy. For antiviral medications, acyclovir and trichloroacetic acid are safe to use in pregnancy. Docosanol, imiquimod and penciclovir are likely safe, but should be utilized as second\u2010line agents. Podofilox and podophyllin resin should be avoided. For antifungal medications, clotrimazole, miconazole and nystatin are considered first\u2010line agents. Butenafine, ciclopirox, naftifine, oxiconazole and terbinafine may be utilized after the above agents. Econazole should be avoided during the first trimester and used sparingly during 2nd and 3rd trimester. Ketoconazole and selenium sulphide are likely safe, but should be employed in limited areas for brief periods.<\/jats:p>","DOI":"10.1111\/jdv.14297","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T18:06:07Z","timestamp":1493316367000},"page":"1440-1446","source":"Crossref","is-referenced-by-count":37,"title":["Topical antiviral and antifungal medications in pregnancy: a review of safety profiles"],"prefix":"10.1111","volume":"31","author":[{"given":"V.M.","family":"Patel","sequence":"first","affiliation":[{"name":"Dermatology and Pathology Rutgers New Jersey Medical School Newark NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Dermatology and Pathology Rutgers New Jersey Medical School Newark NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.C.","family":"Lambert","sequence":"additional","affiliation":[{"name":"Dermatology and Pathology Rutgers New Jersey Medical School Newark NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,4]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2012.00126"},{"key":"e_1_2_5_3_1","volume-title":"Drugs During Pregnancy and Lactation","author":"Schaefer C","year":"2014"},{"key":"e_1_2_5_4_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1542\/peds.93.1.137","article-title":"The transfer of drugs and other chemicals into human milk","volume":"93","author":"Kauffman RE","year":"1994","journal-title":"Pediatrics"},{"key":"e_1_2_5_5_1","unstructured":"GlaxoSmithKline.Zovirax package insert.2005. URLhttps:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=0da14760-1131-4936-9a42-c40fc4db5cd0(last accessed: 15 October 2016)."},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1206"},{"key":"e_1_2_5_7_1","volume-title":"Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk","author":"Briggs G","year":"2014"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.01464.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.010"},{"key":"e_1_2_5_10_1","first-page":"427","article-title":"Safety of antiviral medication for the treatment of herpes during pregnancy","volume":"57","author":"Kang S\u2010H","year":"2011","journal-title":"Can Fam Physician"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.30313"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.12.2567"},{"key":"e_1_2_5_13_1","volume-title":"USP DI. Drug Information for the Health Care Professional","author":"United States Pharmacopeial Convention","year":"2003"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.7.1105"},{"key":"e_1_2_5_15_1","first-page":"1428","article-title":"Imiquimod rejuvenated skin: an exciting concept","volume":"33","author":"Micali G","year":"2007","journal-title":"Dermatol Surg"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-0997(1998)6:2<49::AID-IDOG3>3.0.CO;2-2"},{"key":"e_1_2_5_17_1","unstructured":"3M Health Care.Aldara package insert.2015. URLhttps:\/\/dailymed.nlm.nih.gov\/dailymed\/archives\/fdaDrugInfo.cfm?archiveid=164223(last accessed: 15 October 2016)."},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2004.00245.x"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2005.06.001"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2007.09.020"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/14767058.2011.600795"},{"key":"e_1_2_5_22_1","volume-title":"Clinical Pharmacology During Pregnancy","author":"Mattison D","year":"2012"},{"key":"e_1_2_5_23_1","unstructured":"Prestium Pharma.Denavir package insert.2013. URLhttps:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=14d60b68-e5dd-475a-8517-576eb7894683(last accessed: 15 October 2016)."},{"key":"e_1_2_5_24_1","unstructured":"DPT Laboratories.Condylox gel package insert.2015. URLhttps:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=ada310c0-0811-4e6b-97cc-9653b17d66d8(Last accessed: 05 October 2016)."},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-113-28296"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1956.tb00013.x"},{"key":"e_1_2_5_27_1","volume-title":"Williams Obstetrics","author":"Cunningham F","year":"2014"},{"key":"e_1_2_5_28_1","first-page":"265","article-title":"Screening and treatment for sexually transmitted infections in pregnancy","volume":"76","author":"Majeroni BA","year":"2007","journal-title":"Am Fam Physician"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0095-4543(05)70146-9"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(62)90387-2"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5823.391"},{"key":"e_1_2_5_32_1","unstructured":"Perrigo.Podocon package insert.2014. URLhttps:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=de96dc6e-e6d1-4383-9ce1-4d06bac08e00(last accessed: 16 October 2016)."},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603000903"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000018063"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)93025-7"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420370310"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.03.018"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1551-8833.1983.tb05213.x"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(87)70181-9"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420400506"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(88)90375-4"},{"key":"e_1_2_5_42_1","unstructured":"Mylan Pharmaceuticals.Mentax package insert.2013. URLhttps:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=167ecefd-4553-41b8-8160-81a48dbca076(last accessed: 24 October 2016)."},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2006.01.001"},{"key":"e_1_2_5_44_1","unstructured":"Contract Pharmaceuticals.Loprox package insert.2012. URLhttps:\/\/dailymed.nlm.nih.gov\/dailymed\/archives\/fdaDrugInfo.cfm?archiveid=74427(Last accessed: 05 October 2016)."},{"key":"e_1_2_5_45_1","unstructured":"Glenmark Pharmaceutical.Ciclopirox package insert.2015. URLhttps:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=3c22416e-4293-4ba5-a983-137cbc6022db(last accessed: 22 October 2016)."},{"key":"e_1_2_5_46_1","unstructured":"Schering Corporation.Lotrisone cream package insert.2009. URLhttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020010s021lbl.pdf(last accessed: 25 October 2016)."},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199907000-00016"},{"key":"e_1_2_5_48_1","first-page":"102","article-title":"A comparative trial of six day therapy with clotrimazole and nystatin in pregnant patients with vaginal candidiasis","volume":"50","author":"Tan C","year":"1974","journal-title":"Postgrad Med J"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016347809156527"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007997709115284"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1086\/514977"},{"key":"e_1_2_5_52_1","unstructured":"Merz Pharmaceuticals.Econazole nitrate cream package insert.2014. URLhttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/018751s023lbl.pdf(last accessed: 15 October 2016)"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(03)00192-1"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007998509109606"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1081\/ERC-120015045"},{"key":"e_1_2_5_56_1","volume-title":"Mosby's Drug Reference for Health Professions","author":"Mosby","year":"2015"},{"key":"e_1_2_5_57_1","unstructured":"BFARM.Core safety profile: topical ketoconazole.2011. URLhttp:\/\/www.bfarm.de\/SharedDocs\/Downloads\/EN\/Drugs\/vigilance\/PSURs\/csp\/k-l\/ketoconazole-topical.pdf(last accessed: 26 October 2016)."},{"key":"e_1_2_5_58_1","unstructured":"Janssen Pharmaceuticals.Nizoral package insert.2013. URLhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018533s040lbl.pdf(last accessed: 22 October 2016)."},{"key":"e_1_2_5_59_1","first-page":"398","article-title":"Limb malformations in a case of hydrops fetalis with ketoconazole use during pregnancy","volume":"237","author":"Lind J","year":"1985","journal-title":"Arch Gynecol"},{"key":"e_1_2_5_60_1","volume-title":"The Complete Guide to Medications During Pregnancy and Breastfeeding","author":"Weiner C","year":"2013"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku355"},{"key":"e_1_2_5_62_1","unstructured":"Pharmaceuticals O.Monistat package insert.2006. URLhttps:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=a1cd682a-fa73-491d-b276-8c96d801b083&type=display(last accessed: 22 October 2016)."},{"key":"e_1_2_5_63_1","first-page":"751","article-title":"Pregnancy outcomes after first\u2010trimester vaginitis drug therapy","volume":"69","author":"Rosa F","year":"1987","journal-title":"Obstet Gynecol"},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2004.11.012"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1741-4520.2004.00007.x"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200023010-00005"},{"key":"e_1_2_5_67_1","unstructured":"Merz Pharmaceuticals.Naftin package insert.2013. URLhttp:\/\/www.naftin.com\/wp-content\/uploads\/NAFTIN-Cream-2-PI.pdf(last accessed: 15 October 2016)."},{"key":"e_1_2_5_68_1","unstructured":"Perrigo.Nystatin cream package insert.2015. URLhttps:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=e630aa3d-11a6-4300-942a-cbdf2d016f77(last accessed: 22 October 2016)."},{"key":"e_1_2_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(74)90348-2"},{"key":"e_1_2_5_70_1","first-page":"403","article-title":"Comparative evaluation of Monistat and Mycostatin in the treatment of vulvovaginal candidiasis","volume":"44","author":"Davis J","year":"1974","journal-title":"Obstet Gynecol"},{"key":"e_1_2_5_71_1","first-page":"491","article-title":"Recurrence of vulvovaginal candidosis during pregnancy: comparison of miconazole vs nystatin treatment","volume":"48","author":"Wallenburg HC","year":"1976","journal-title":"Obstet Gynecol"},{"key":"e_1_2_5_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365540310017069"},{"key":"e_1_2_5_73_1","unstructured":"PharmaDerm.Oxistat package insert.2014. URLhttps:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b87a89d2-6e45-4eb8-be2c-7f55f34d61e5(last accessed: 21 October 2016)."},{"key":"e_1_2_5_74_1","doi-asserted-by":"publisher","DOI":"10.5005\/jp\/books\/11875"},{"key":"e_1_2_5_75_1","first-page":"249","volume-title":"Skin Changes and Disease in Pregnancy","author":"Sasseville D","year":"1996"},{"key":"e_1_2_5_76_1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/archderm.1993.01680260118023","article-title":"Lack of serum selenium rise after overnight application of selenium sulfide","volume":"129","author":"Kalivas J","year":"1993","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_77_1","unstructured":"Novartis Pharmaceuticals.Lamisil package insert.2001. URLhttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/1999\/20846s001lbl.pdf(last accessed: 15 October 2016)."},{"key":"e_1_2_5_78_1","first-page":"390","article-title":"Pregnancy outcome following gestational exposure to terbinafine: a prospective comparative study","volume":"67","author":"Sarkar M","year":"2003","journal-title":"Clin Mol Teratol"},{"key":"e_1_2_5_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0000000000000089"},{"key":"e_1_2_5_80_1","volume-title":"WHO Model Prescribing Information: Drugs Used in Skin Diseases","author":"World Health Organization","year":"1997"},{"key":"e_1_2_5_81_1","first-page":"47","article-title":"Transdermal drug delivery systems: approaches and advancements in drug absorption through skin","volume":"20","author":"Jhawat V","year":"2013","journal-title":"Int J Pharm Sci Rev Res"},{"key":"e_1_2_5_82_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1984-82502013000300004"},{"key":"e_1_2_5_83_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2000.009003165.x"},{"key":"e_1_2_5_84_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018841111922"},{"key":"e_1_2_5_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(00)00350-3"},{"key":"e_1_2_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.01.010"},{"key":"e_1_2_5_87_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.024794"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14297","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T19:55:00Z","timestamp":1695498900000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,4]]},"references-count":86,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/jdv.14297"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14297","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,4]]}}}